Search Results for "Rosiglitazone" - 138 interactions found in 25 entries.

Entry-ID
Interactor1 (Subject) Interaction type Interactor2 (Object) additional information
PubMed-ID
Diseases
436
1913 Rosiglitazone increases_activity of GPAT3
17170135 Diabetes mellitus, type II
Insulin resistance
480
2253 Rosiglitazone increases_activity of AMPK in skeletal muscle; with increase of the AMP:ATP ratio
2278 Rosiglitazone increases_phosphorylation of AMPK alpha chain in skeletal muscle; at Thr172 of AMPK alpha chain
2279 Rosiglitazone increases_phosphorylation of ACACA in skeletal muscle
11994296 Diabetes mellitus, type II
Insulin resistance
1,196
8007 Rosiglitazone decreases_expression of ADAM8 in ob/ob mice
8008 Rosiglitazone decreases_expression of ITGAM in ob/ob mice
8009 Rosiglitazone decreases_expression of EMR1 in ob/ob mice
8011 Rosiglitazone decreases_expression of CD68 in ob/ob mice
14679177 Diabetes mellitus, type II
Insulin resistance
1,405
9756 Rosiglitazone increases_expression of GPX3 in adipose tissue; in db/db mice
9759 Rosiglitazone decreases_activity of response to oxidative stress in adipose tissue; in db/db mice
9761 Rosiglitazone NOT affects_expression of GPX3 in kidney
18562625 Diabetes mellitus, type II
Obesity
Insulin resistance
1,819
13645 Rosiglitazone decreases_activity of inflammatory response if induced by FFA
13647 Rosiglitazone decreases_activity of Fatty acid
17916553 Diabetes mellitus, type II
Insulin resistance
2,052
16429 Rosiglitazone decreases_activity of Diabetes mellitus, type II
16431 Rosiglitazone decreases_activity of hyperglycemia
21116607 Diabetes mellitus, type II
Insulin resistance
2,278
19546 Rosiglitazone decreases_activity of Alzheimer disease in Tg2576 mice
19547 Rosiglitazone affects_activity of behavior in Tg2576 mice
19548 Rosiglitazone decreases_quantity of Amyloid beta peptide (42) in brain; of Tg2576 mice
19549 Rosiglitazone increases_activity of memory (spatial working and reference memory)
19550 Rosiglitazone decreases_quantity of Amyloid beta peptide (42)
19551 Rosiglitazone NOT affects_quantity of Amyloid beta peptide (40)
19593 Rosiglitazone decreases_activity of cognitive impairment in a subset of AD patients
21345168 Alzheimer disease
2,306
19821 Rosiglitazone decreases_quantity of Tetradecanoylcarnitine in blood plasma
19824 Rosiglitazone decreases_quantity of Palmitoylcarnitine in blood plasma
19825 Rosiglitazone decreases_quantity of Stearoylcarnitine in blood plasma
19826 Rosiglitazone decreases_quantity of Hexadecenoylcarnitine in blood plasma
19827 Rosiglitazone decreases_quantity of Octadecenylcarnitine in blood plasma
19828 Rosiglitazone decreases_quantity of Linoleylcarnitine in blood plasma
19831 Rosiglitazone decreases_quantity of PC ee C42:6 in blood plasma
19841 Rosiglitazone decreases_quantity of PC aa C40:5 in blood plasma
19842 Rosiglitazone decreases_quantity of PC aa C40:6 in blood plasma
19843 Rosiglitazone decreases_quantity of PC ee C42:5 in blood plasma
19844 Rosiglitazone increases_quantity of PIP3 aa C42:3 in blood plasma
19845 Rosiglitazone increases_quantity of PIP2 aa C36:0 in blood plasma
19846 Rosiglitazone increases_quantity of Glycerophosphatidylinositol in blood plasma
19847 Rosiglitazone increases_quantity of Methylglutarylcarnitine in blood plasma; in diabetic mice
19848 Rosiglitazone decreases_quantity of Methylglutarylcarnitine in blood plasma; in healthy mice
18372322 Diabetes mellitus, type II
Insulin resistance
2,311
19850 Rosiglitazone increases_activity of glucose import in brown adipose tissue; dependent on p38-mitogen-activated protein kinase
19852 Rosiglitazone increases_transport of SLC2A4 to the plasma membrane in brown adipose tissue
19855 Rosiglitazone NOT affects_expression of SLC2A4 in brown adipose tissue
19857 Rosiglitazone NOT affects_quantity of SLC2A4 in brown adipose tissue
20396 Rosiglitazone increases_phosphorylation of IRS1 in brown adipose tissue; at Tyr residues of IRS1
20397 Rosiglitazone increases_phosphorylation of IRS2 in brown adipose tissue; at Tyr residues of IRS2
20398 Rosiglitazone increases_activity of Phosphatidylinositol 3-kinase in brown adipose tissue
20399 Rosiglitazone increases_activity of AKT1 in brown adipose tissue
20400 Rosiglitazone NOT affects_activity of PRKCZ in brown adipose tissue
20401 Rosiglitazone increases_expression of INSR in brown adipose tissue
20404 Rosiglitazone increases_phosphorylation of Insulin receptor beta subunit in brown adipose tissue; at Tyr residues after insulin stimulation
20406 Rosiglitazone decreases_phosphorylation of Insulin receptor beta subunit in brown adipose tissue; at Ser residues after insulin stimulation
20408 Rosiglitazone increases_phosphorylation of PTPN1 in brown adipose tissue; at Tyr residues after insulin stimulation
20410 Rosiglitazone decreases_activity of PTPN1 in brown adipose tissue; after insulin stimulation
20414 Rosiglitazone increases_activity of Insulin receptor in brown adipose tissue
20418 Rosiglitazone increases_activity of increased insulin sensitivity in brown adipose tissue
14595539 Diabetes mellitus, type II
Insulin resistance
2,337
20366 Rosiglitazone increases_activity of learning or memory in Tg2576 mice
20371 Rosiglitazone decreases_quantity of Corticosterone in Tg2576 mice
16515786 Alzheimer disease
2,876
26479 Rosiglitazone decreases_expression of RETN in adipose tissue
11201732 Diabetes mellitus, type II
Obesity
Insulin resistance
3,281
30186 Rosiglitazone decreases_activity of increased circulating NAMPT level
30187 Rosiglitazone decreases_activity of increased circulating NAMPT level
30193 Rosiglitazone decreases_expression of NAMPT
30194 Rosiglitazone decreases_expression of IKBKB
30195 Rosiglitazone decreases_expression of MAPK8/9
21694775 Diabetes mellitus, type II
Insulin resistance
3,562
33200 Rosiglitazone decreases_quantity of Glutamate in blood serum; in diabetic patients
33201 Rosiglitazone decreases_quantity of Maltose in blood serum; in diabetic patients
33202 Rosiglitazone decreases_quantity of Butanoic acid in blood serum; in diabetic patients
33203 Rosiglitazone increases_quantity of D-Glucuronolactone in blood serum; in diabetic patients
33204 Rosiglitazone decreases_quantity of Palmitic acid in blood serum; in diabetic patients
33205 Rosiglitazone decreases_quantity of Oleic acid in blood serum; in diabetic patients
33210 Rosiglitazone decreases_quantity of Glutamate in blood serum; in diabetic patients
33213 Rosiglitazone affects_quantity of Fructose in blood serum; in diabetic patients
33215 Rosiglitazone affects_quantity of alpha-D-Galactose in blood serum; in diabetic patients
33217 Rosiglitazone affects_quantity of Mannose in blood serum; in diabetic patients
33219 Rosiglitazone affects_quantity of Maltose in blood serum; in diabetic patients
33222 Rosiglitazone decreases_quantity of Glucose in blood serum; in diabetic patients
33223 Rosiglitazone increases_quantity of Glycerol 3-phosphate in blood serum; in diabetic patients
19714868 Diabetes mellitus, type II
Insulin resistance
3,703
35914 Rosiglitazone decreases_activity of increased circulating insulin level in PCOS women
35918 Rosiglitazone decreases_activity of increased androgen level in PCOS women
22953622 Diabetes mellitus, type II
Insulin resistance
Polycystic ovary syndrome 1
3,704
35923 Rosiglitazone NOT decreases_quantity of ACTH in patients with Cushing's disease
35924 Rosiglitazone NOT decreases_activity of cortisol secretion in patients with Cushing's disease
35925 Rosiglitazone NOT decreases_activity of Cushing syndrome in patients with Cushing's disease
35926 Rosiglitazone affects_activity of PPARG
16430724 Cushing syndrome
3,759
36591 Rosiglitazone increases_activity of decreased circulating homocysteine level in blood serum
36592 Rosiglitazone NOT affects_activity of abnormal vitamin B12 level in blood serum
36593 Rosiglitazone NOT affects_activity of abnormal folic acid level in blood serum
36601 Rosiglitazone NOT affects_activity of decreased body weight
36602 Rosiglitazone increases_activity of decreased circulating triglyceride level in blood plasma
36603 Rosiglitazone increases_activity of decreased circulating LDL cholesterol level in blood plasma
36604 Rosiglitazone increases_activity of decreased circulating cholesterol level in blood plasma
36605 Rosiglitazone increases_activity of decreased glycosylated hemoglobin level in blood plasma
36606 Rosiglitazone increases_activity of decreased circulating insulin level in blood plasma
36607 Rosiglitazone decreases_activity of Insulin resistance
17331860 Diabetes mellitus, type II
Insulin resistance
3,975
40413 Rosiglitazone increases_quantity of Valine in blood plasma; in male and female type 2 diabetic patients
40414 Rosiglitazone decreases_quantity of Hippurate in urine; in type 2 diabetic patients
40415 Rosiglitazone increases_quantity of Tyrosine in urine; in type 2 diabetic patients
40416 Rosiglitazone increases_quantity of Phenylalanine in urine; in type 2 diabetic patients
40417 Rosiglitazone increases_quantity of Leucine in blood plasma; in male and female type 2 diabetic patients
40418 Rosiglitazone increases_quantity of Isoleucine in blood plasma; in male and female type 2 diabetic patients
40419 Rosiglitazone increases_quantity of Alanine in blood plasma; in male and female type 2 diabetic patients
40420 Rosiglitazone increases_quantity of Glutamine/Glutamate in blood plasma; in male and female type 2 diabetic patients
40421 Rosiglitazone increases_quantity of Citrate in blood plasma; in female type 2 diabetic patients
40422 Rosiglitazone decreases_quantity of Lactate in blood plasma; in female type 2 diabetic patients
40423 Rosiglitazone decreases_quantity of Acetate in blood plasma; in female type 2 diabetic patients
40424 Rosiglitazone decreases_quantity of Tyrosine in blood plasma; in female type 2 diabetic patients
40425 Rosiglitazone decreases_quantity of Phenylalanine in blood plasma; in female type 2 diabetic patients
40426 Rosiglitazone NOT affects_quantity of Lipid in blood plasma; in male and female type 2 diabetic patients
40427 Rosiglitazone increases_quantity of Threonine in blood plasma; in male type 2 diabetic patients
17488363 Diabetes mellitus, type II
Insulin resistance
4,329
44324 Rosiglitazone interacts (colocalizes) with PPARG in NIH-3T3 cells
22872237 Metabolic
Lipodystrophy
4,368
44563 Rosiglitazone increases_activity of FLT3L-FLT3 signaling
44752 Rosiglitazone increases_activity of FLT3
21967974 Metabolic
4,369
44564 Rosiglitazone increases_activity of PPARG
21967974 Metabolic
4,904
48541 Rosiglitazone increases_activity of Cardiovascular disease
48578 CYP2C8 decreases_quantity of Rosiglitazone
48580 CYP2C9 decreases_quantity of Rosiglitazone
48581 Gemfibrozil affects_activity of Rosiglitazone
48582 Trimethoprim affects_activity of Rosiglitazone
48584 Ketoconazole affects_activity of Rosiglitazone
48589 Rosiglitazone NOT affects_activity of Digoxin
48591 Rosiglitazone NOT affects_activity of Efavirenz
48593 Rosiglitazone NOT affects_activity of Lopinavir
48594 Rosiglitazone NOT affects_activity of Metformin
48595 Rosiglitazone NOT affects_activity of Oral contraceptive
48596 Rosiglitazone decreases_activity of SLCO1B1
48646 Sitagliptin NOT affects_activity of Rosiglitazone
22475684 Diabetes mellitus, type II
Insulin resistance
5,084
49942 Rosiglitazone decreases_activity of Insulin resistance induced by olanzapine treatment
49943 Rosiglitazone decreases_activity of hyperglycemia induced by olanzapine treatment
22640703 Diabetes mellitus, type II
Schizophrenia
Insulin resistance
5,334
52531 Rosiglitazone increases_expression of PPARGC1A in skeletal muscle; in obese diabetic men
52532 Rosiglitazone increases_expression of PPARD in skeletal muscle; in obese diabetic men
52533 Rosiglitazone increases_activity of increased insulin sensitivity in skeletal muscle; in obese diabetic men
52534 Rosiglitazone increases_activity of SDH in skeletal muscle; in obese diabetic men
17310221 Diabetes mellitus, type II
Insulin resistance
5,678
53962 Rosiglitazone increases_expression of SLC2A2
53966 Rosiglitazone increases_expression of GCK
53967 Rosiglitazone increases_expression of NEUROD1
53968 Rosiglitazone increases_activity of insulin secretion
53969 Rosiglitazone increases_activity of insulin biosynthetic process
18191635 Diabetes mellitus, type II
Insulin resistance
MODY, type VI
6,509
61842 Rosiglitazone decreases_activity of ACACA in muscle
61848 Rosiglitazone affects_activity of AMPK in muscle
61856 Rosiglitazone increases_activity of fatty acid beta-oxidation in muscle
61878 Rosiglitazone affects transport of CD36 to plasma membrane, in muscle
61879 Rosiglitazone affects transport of SLC27A4 to plasma membrane, in muscle
16873691 Diabetes mellitus, type II
Insulin resistance
-->